| Symbol | AUPH |
|---|---|
| Name | AURINIA PHARMACEUTICALS INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | #140, 14315 - 118 AVENUE, EDMONTON, A0 T5L 4S6 |
| Telephone | 250-744-2487 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001600620 |
| Description | None |
Robertson Stephen P. 🔴 sold 11.9K shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.95 Transaction Date: Sep 10, 2026 | Filing ID: 000068
Read moreNew Form SCHEDULE 13D/A - Aurinia Pharmaceuticals Inc. <b>Filed:</b> 2026-08-26 <b>AccNo:</b> 0001104659-26-101785 <b>Size:</b> 27 KB
Read moreRobertson Stephen P. 🔴 sold 21.0K shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 Transaction Date: Aug 21, 2026 | Filing ID: 000013
Read more📋 Stephen P. Robertson (Officer) plans to sell 47K shares of Aurinia Pharmaceuticals Inc. (at $15.30 each, total $719K) Filed: Aug 21, 2026 | ID: 000010
Read moreAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Read moreAurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Read moreAurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Read moreAurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
Read more